<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Fintepla</title>
    <style>
      .sub-copy a:hover{text-decoration:underline}
    </style>
    <style type="text/css">
      @font-face {
              font-family: "Lato";
              src: url("fonts/lato-regular-webfont.woff") format("woff"),
                url("fonts/Lato-Regular.ttf") format("truetype")
                  url("/fonts/lato-regular-webfont.woff2") format("woff2");
            }
            @media screen and (max-width: 400px) {
              .narrow--dt {
                padding-left: 0;
                padding-right: 0;
              }
              .narrow__2--dt {
                padding-left: 20px;
                padding-right: 20px;
              }
            }
    </style>
  </head>
  <body style="margin:0;padding:0;">
    <center class="wrapper" style="width:100%;table-layout:fixed;background-color:#f6f9fc;padding-bottom:40px;">
      <div class="webkit" style="max-width:600px;background-color:#ffffff;">
        <table class="outer" style='width:100%;max-width:600px;margin:0 auto;border-spacing:0;font-family:"Lato", "Arial", sans-serif;color:#4a4a4a;'>
          <!-- Banner Header -->
          <tr>
            <td style="padding:0;">
              <table style="width:100%;border-spacing:0;">
                <tr>
                  <td style="padding:0;background-color: #682b8d; text-align: center;">
                    <p class="sub-copy" style="font-size:12px;line-height:18px;color:#63585c;color: #ffffff;">
                      INTENDED FOR HEALTHCARE PROFESSIONALS IN THE UK ONLY |
                      <a href="https://www.zogenixresources.eu/Fintepla-fenfluramine-Prescribing-Information.pdf" class="sub-copy" style="font-size:12px;line-height:18px;color:#63585c;color:#682b8d;text-decoration:underline;color: #ffffff;">Prescribing information</a>
                    </p>
                  </td>
                </tr>
              </table>
            </td>
          </tr>
          <!-- Header Logos -->
          <tr>
            <td class="narrow" style="padding:0;padding-left:20px;padding-right:20px;padding-top: 30px; padding-bottom: 35px;">
              <table style="width:100%;border-spacing:0;">
                <tr>
                  <td style="padding:0;vertical-align: top;">
                    <img src="img/main-logo.png" alt="" width="143" style="border:0;"/>
                  </td>
                  <td style="padding:0;vertical-align: top;">
                    <img src="img/zogenix-purple.png" alt="" width="111" style="border:0;float: right;">
                  </td>
                </tr>
              </table>
            </td>
          </tr>
          <!-- Banner Image -->
          <tr>
            <td class="narrow--dt" style="padding:0;padding-left:20px;padding-right:20px;">
              <img src="img/banner.png" alt="Banner" width="600px;" style="border:0;max-width: 100%;">
            </td>
          </tr>
          <!-- Banner Text -->
          <tr>
            <td class="narrow__2--dt" style="padding:0;padding-left:40px;padding-right:40px;">
              <table width="100%" style="width:100%;border-spacing:0;background-color: #f5f2f7;">
                <tr>
                  <td style="padding:0;">
                    <table style="width:100%;border-spacing:0;">
                      <tr>
                        <td class="narrow" style="padding:0;padding-left:20px;padding-right:20px;">
                          <div style="
                              width: 3px;
                              height: 37px;
                              background-color: #d23d56;
                            "></div>
                        </td>
                        <td style="padding:0;padding-right: 20px;">
                          <p style="font-size: 18px; color: #682b8d">
                            A NEW ADVANCE IN THE TREATMENT OF PATIENTS WITH
                            DRAVET SYNDROME
                          </p>
                        </td>
                      </tr>
                    </table>
                  </td>
                </tr>
              </table>
            </td>
          </tr>
          <!-- Body Copy -->
          <tr>
            <td class="narrow" style="padding:0;padding-left:20px;padding-right:20px;padding-top: 15px; padding-bottom: 15px;">
              <p class="copy" style="padding-bottom:5px;font-size:15px;line-height:25px;color:#66575c;">Dear {{ name }},</p>
              <p class="copy" style="padding-bottom:5px;font-size:15px;line-height:25px;color:#66575c;">
                We&apos;re excited to announce that Finteplaâ–¼(fenfluramine) is
                due to be launched in the UK in 2022! Fintepla is indicated for
                the treatment of seizures associated with Dravet syndrome as an
                add-on therapy to other antiepileptic medicines for patients 2
                years of age and older.<sup style="line-height:15px;">1</sup>
              </p>
              <p class="copy" style="padding-bottom:5px;font-size:15px;line-height:25px;color:#66575c;">
                You are invited to attend the launch meeting which will be held
                in Manchester and London. Both will be hybrid meetings enabling
                online and in person attendance.
              </p>
            </td>
          </tr>
          <!-- Register Interest Top -->
          <tr>
            <td style="padding:0;">
              <table style="width:100%;border-spacing:0;">
                <tr>
                  <td style="padding:0;
                      padding-top: 10px;
                      padding-bottom: 35px;
                      text-align: center;
                      vertical-align: middle;
                    ;">
                    <a href="https://zogenix.wavecast.io/fintepla-2022/registration?utm_source=Digital&utm_medium=Email&utm_campaign=Register_interest" class="register-btn" style="color:#682b8d;text-decoration:none;font-size:15px;font-weight:bold;padding-top:15px;padding-bottom:15px;padding-left:30px;padding-right:30px;border-width:2px;border-style:solid;border-color:#682b8d;">REGISTER YOUR INTEREST</a>
                  </td>
                </tr>
              </table>
            </td>
          </tr>
          <tr>
            <td class="narrow" style="padding:0;padding-left:20px;padding-right:20px;padding-bottom: 15px;">
              <p class="sub-copy" style="font-size:12px;line-height:18px;color:#63585c;">
                These live interactive sessions have been initiated and funded
                by Zogenix.
              </p>
            </td>
          </tr>
          <!-- Topics Section -->
          <tr>
            <td style="padding:0;">
              <table style="width:100%;border-spacing:0;">
                <tr>
                  <td style="padding:0;
                      text-align: center;
                      vertical-align: middle;
                      background-color: #682b8d;
                    ;">
                    <p style="font-weight: bold; font-size: 17px; color: #ffffff">
                      TOPICS TO BE COVERED WILL INCLUDE:
                    </p>
                  </td>
                </tr>
                <tr>
                  <td style="padding:0;background-color: #f5f2f7;">
                    <ul style="padding-top:5px;padding-bottom:5px;padding-left:40px;padding-right:40px;">
                      <li style="font-size:15px;line-height:25px;color:#682b8d;">
                        <p style="padding-left:20px;">
                          An update on the NICE appraisal process for the use of
                          Fintepla to treat patients with Dravet syndrome
                        </p>
                      </li>
                      <li style="font-size:15px;line-height:25px;color:#682b8d;">
                        <p style="padding-left:20px;">
                          Current diagnosis and treatment landscapes for Dravet
                          syndrome
                        </p>
                      </li>
                      <li style="font-size:15px;line-height:25px;color:#682b8d;">
                        <p style="padding-left:20px;">
                          Exploring unmet needs for Dravet syndrome patients and
                          their families
                        </p>
                      </li>
                      <li style="font-size:15px;line-height:25px;color:#682b8d;">
                        <p style="padding-left:20px;">
                          Fintepla clinical trial data and Real World Evidence
                        </p>
                      </li>
                    </ul>
                  </td>
                </tr>
              </table>
            </td>
          </tr>
          <!-- Forward Invite -->
          <tr>
            <td class="narrow" style="padding:0;padding-left:20px;padding-right:20px;">
              <p class="copy" style="padding-bottom:5px;font-size:15px;line-height:25px;color:#66575c;
                  max-width: 420px;
                  margin: 15px auto;
                  padding-top: 15px;
                  padding-bottom: 15px;
                  color: #682b8d;
                  text-align: center;
                ;">
                Please forward this invite to any of your UK HCP colleagues who
                you think will be interested in hearing about the launch of
                Fintepla. We look forward to welcoming you.
              </p>
            </td>
          </tr>
          <!-- Register Interest Top -->
          <tr>
            <td class="narrow" style="padding:0;padding-left:20px;padding-right:20px;
                background-color: #682b8d;
                padding-top: 35px;
                padding-bottom: 35px;
              ;">
              <table style="width:100%;border-spacing:0;">
                <tr>
                  <td style="padding:0;
                      padding-top: 10px;
                      padding-bottom: 35px;
                      text-align: center;
                      vertical-align: middle;
                    ;">
                    <a href="https://zogenix.wavecast.io/fintepla-2022/registration?utm_source=Digital&utm_medium=Email&utm_campaign=Register_interest" class="register-btn register-btn--white" style="color:#682b8d;text-decoration:none;font-size:15px;font-weight:bold;padding-top:15px;padding-bottom:15px;padding-left:30px;padding-right:30px;border-width:2px;border-style:solid;border-color:#682b8d;color:#ffffff;border-color:#ffffff;">REGISTER YOUR INTEREST</a>
                  </td>
                </tr>
                <tr>
                  <td style="padding:0;">
                    <p style="color: #ffffff; text-align: center">
                      and look out for further information, coming soon.
                    </p>
                  </td>
                </tr>
                <tr>
                  <td style="padding:0;text-align: center;">
                    <p style="color: #ffffff">
                      Best Wishes from the Zogenix UK Team
                    </p>
                    <img width="80" src="img/zogenix-white.png" alt="Zogenix Logo" style="border:0;">
                  </td>
                </tr>
              </table>
            </td>
          </tr>
          <!-- Footer 1 -->
          <tr>
            <td class="narrow" style="padding:0;padding-left:20px;padding-right:20px;padding-top: 20px;">
              <table style="width:100%;border-spacing:0;">
                <tr>
                  <td style="padding:0;">
                    <p class="sub-copy" style="font-size:12px;line-height:18px;color:#63585c;">
                      For any medical questions please email
                      <a href="mailto:medinfo.eu@zogenix.com" style="color:#682b8d;text-decoration:none;">medinfo.eu@zogenix.com</a>
                    </p>
                  </td>
                </tr>
                <tr>
                  <td style="padding:0;">
                    <p style="
                        font-size: 12px;
                        font-weight: bold;
                        color: #682b8d;
                        line-height: 15px;
                      ">
                      Reference:
                    </p>
                    <ol style="padding-top:5px;padding-bottom:5px;padding-left:40px;padding-right:40px;padding-top:0;padding-left:16px;font-size:12px;">
                      <li style="padding-left:24px;line-height:12px;">
                        <p style="line-height:12px;">Fintepla Summary of Product Characteristics.</p>
                      </li>
                    </ol>
                  </td>
                </tr>
              </table>
            </td>
          </tr>
          <!-- Footer 2 -->
          <tr>
            <td class="narrow" style="padding:0;padding-left:20px;padding-right:20px;">
              <p class="sub-copy footer-box" style="font-size:12px;line-height:18px;color:#63585c;max-width:560px;border-width:1px;border-style:solid;border-color:#63585c;padding-top:20px;padding-bottom:20px;padding-right:43px;padding-left:43px;text-align:center;">
                Adverse events should be reported. Reporting forms and
                information can be found at
                <a href="https://yellowcard.mhra.gov.uk/" style="color:#682b8d;text-decoration:none;">https://yellowcard.mhra.gov.uk/</a>
                or search for MHRA Yellow Card in the Google Play or Apple App
                Store. Adverse events should also be reported to Zogenix
                International Limited on
                <a href="tel:+448000608767" style="color:#682b8d;text-decoration:none;">0800 060 8767</a> or email
                <a href="mailto:medinfo.eu@zogenix.com" style="color:#682b8d;text-decoration:none;">medinfo.eu@zogenix.com</a>.
              </p>
            </td>
          </tr>
          <!-- Footer 3 -->
          <tr>
            <td class="narrow" style="padding:0;padding-left:20px;padding-right:20px;padding-bottom: 10px;">
              <table style="width:100%;border-spacing:0;">
                <tr>
                  <td style="padding:0;vertical-align: top;">
                    <p class="sub-copy" style="font-size:12px;line-height:18px;color:#63585c;">UK-FIN1-2100081 December 2021</p>
                  </td>
                  <td style="padding:0;vertical-align: top; float: right;">
                    <p class="sub-copy" style="font-size:12px;line-height:18px;color:#63585c;">
                      Fintepla is currently under NICE evaluation.
                    </p>
                  </td>
                </tr>
              </table>
            </td>
          </tr>
        </table>
      </div>
    </center>
  </body>
</html>